Overview
23andMe is a leading personal genomics platform that utilizes high-throughput genotyping technology to decode individual genetic data. By 2026, the company has transitioned from simple ancestry reporting to a sophisticated 'Health-as-a-Service' model, leveraging Polygenic Risk Scores (PRS) and Machine Learning to predict chronic disease predispositions. Their technical architecture revolves around the Illumina Infinium Global Screening Array (GSA), which analyzes hundreds of thousands of variants (SNPs) across the genome. Beyond consumer reports, 23andMe maintains one of the world's largest opt-in genetic databases, facilitating large-scale pharmaceutical research and drug discovery via its internal research pipelines. The platform's 2026 market position is defined by its FDA-cleared health risk reports and its 'Total Health' tier, which incorporates clinical-grade Whole Exome Sequencing (WES) and bi-annual blood testing. This allows users to integrate their static genetic blueprint with dynamic longitudinal biomarkers, providing a holistic view of health. Despite historical data security challenges, the platform has implemented advanced encryption and decentralized data protocols to maintain its status as the primary consumer-facing genetics interface for preventive medicine.